Last --
Change Today 0.00 / 0.00%
Volume 0.0
6869 On Other Exchanges
Symbol
Exchange
6869 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sysmex corp (6869) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYSMEX CORP (6869)

Related News

No related news articles were found.

sysmex corp (6869) Related Businessweek News

No Related Businessweek News Found

sysmex corp (6869) Details

Sysmex Corporation, together with its subsidiaries, engages in the research and development, production, sale, service, and support of diagnostic instruments, reagents, and software worldwide. The company provides diagnostics products for use in the areas of hematology, hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care testing; and laboratory information systems, including La-vietal LS, a clinical testing instrument system that links clinical testing instruments and other systems to provide an efficient operating environment. It also offers particle characterization analyzer products, including FPIA-3000 Flow Particle Image Analyzer, which offers automated analysis of particle size and shape; FPIA-3000 Darkfield unit to analyze samples, such as drugs, mica, and biological cells; and XT-2000iV, an animal blood cell analysis software used in the hematological analysis of laboratory veterinary animals, such as rats, mice, or dogs. In addition, the company provides life sciences solutions comprising automated gene amplification detector, a system for the detection of lymph node metastasis based on the one-step nucleic acid amplification method used for the diagnosis of breast, colon, and stomach cancer lymph node diagnosis in hospitals and other facilities, as well as a laboratory testing service for research involving the risk of recurrence of early-stage breast cancer. Further, it offers ASTRIM SU, a peripheral artery monitoring device that measures hemoglobin levels without blood sampling and is used in fitness centers and various other sites, as well as sells health management support software, which supports health check services at drug-stores and in the healthcare sections of other shops. The company was formerly known as TOA Medical Electronics Co., Ltd., and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

4,848 Employees
Last Reported Date: 06/21/13
Founded in 1968

sysmex corp (6869) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sysmex corp (6869) Key Developments

EMD Millipore Announces Clinical Research, Licensing and Joint Development Agreement with Sysmex Corporation

EMD Millipore announced a clinical research, licensing and joint development agreement with Sysmex Corporation. This collaboration will use EMD Millipore's flow cytometry technology as a platform to accelerate the creation of new, more powerful diagnostic tools for research in blood disorders. If successful, Sysmex and EMD Millipore will collaborate on developing the imaging flow technology platform for future commercialization in hematology. Sysmex is conducting a clinical study assessing EMD Millipore's Amnis imaging flow cytometry technology for hematologic disorders such as leukemia. Once clinical research is complete, both parties intend to combine the imaging flow cytometry technology with Sysmex's technologies to develop new imaging flow cytometry technology that will generate image data of molecular (protein) expression status, as well as the identification of abnormal cells in the blood. Sysmex aims to promote the creation of new diagnostic technologies that will lead to the realization of personalized medicine and contribute to the advancement of healthcare by meeting increasingly diverse and sophisticated testing needs. The first step in the EMD Millipore-Sysmex collaboration will be a clinical trial of the Amnis technology using patient blood samples to detect and characterize leukemic conditions and other hematologic disorders.

Sysmex Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2013; Provides Earnings Guidance for the Year Ending March 31, 2014; Provides Dividend Guidance for the Year Ending March 31, 2014

Sysmex Corporation reported consolidated earnings results for the nine months ended December 31, 2013. For the period, the company reported net sales of JPY 129,849 million, operating income of JPY 22,123 million, ordinary income of JPY 23,159 million and net income of JPY 14,002 million or JPY 135.00 diluted per share as compared to net sales of JPY 101,383 million, operating income of JPY 15,192 million, ordinary income of JPY 15,568 million and net income of JPY 9,518 million or JPY 92.19 diluted per share for the same period a year ago. Income before income taxes and minority interest was JPY 22,936 million compared to JPY 15,299 million a year ago. Net cash provided by operating activities was JPY 22,270 million compared to JPY 16,664 million a year ago. Purchase of property, plant and equipment was JPY 9,109 million compared to JPY 8,165 million a year ago. Purchase of intangible assets was JPY 2,652 million compared to JPY 1,422 million a year ago. The company provided earnings guidance for the year ending March 31, 2014. For the year, the company expects net sales of JPY 180,000 million, operating income of JPY 30,000 million, ordinary income of JPY 30,000 million and net income of JPY 18,500 million or JPY 178.92 per share. For the year ending March 31, 2014, the company expects to pay a dividend of JPY 21.00 per share compared to JPY 23.00 per share a year ago.

Sysmex Corp., Q3 2014 Earnings Call, Feb 05, 2014

Sysmex Corp., Q3 2014 Earnings Call, Feb 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6869:JP ¥3,180.00 JPY +35.00

6869 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $120.60 USD +0.74
BioMerieux €76.62 EUR -0.54
Mindray Medical International Ltd $32.01 USD -0.41
Nihon Kohden Corp ¥4,225 JPY +25.00
PerkinElmer Inc $44.27 USD +0.08
View Industry Companies
 

Industry Analysis

6869

Industry Average

Valuation 6869 Industry Range
Price/Earnings 36.4x
Price/Sales 3.9x
Price/Book 4.9x
Price/Cash Flow 32.3x
TEV/Sales 3.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYSMEX CORP, please visit www.sysmex.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.